The GLP-1 ad wars “Healthy Skepticism” comes weeks after Eli Lilly competitor and Ozempic-maker Novo Nordisk launched a print ...

Hims & Hers Health has blazed a red-hot streak, helped by the growing popularity of weight-loss drugs. But after a massive ...

The life sciences industry experienced a dynamic year in 2024. As the public markets gained traction, IPO activity and venture investment saw ...

Eli Lilly is seeking to further cement its stance as a leader in weight loss drugs in an ad campaign calling out “unapproved” medications.

Eli Lilly launched an ad campaign on Friday, cautioning patients against the risks of unapproved weight-loss drugs in its ...

The molecular glue space has attracted several Big Pharma players over the past few years, including Novo Nordisk, Pfizer and ...

NovoCure's FDA approvals face adoption struggles despite growth. Read why NVCR stock may decline with slow indication ...

KBP Biosciences Pte. Ltd. (the 'Company') today issued a statement addressing a recent decision by the Singapore International Commercial Court ('SICC'), which granted an injunction sought by Novo ...

U.S. Representative Andy Barr (R-KY) introduced H.R. 478, the “Promoting New Bank Formation Act,” which was referred to the ...

Portuguese state-owned bank Caixa Geral de Depositos SA is analyzing the possible acquisition of Novo Banco SA, a smaller ...

Patient advocacy group Patients for Affordable Drugs (P4AD) yesterday filed its fourth amicus brief defending the Biden ...

Ashland is poised for growth with strong FCF, strategic moves, and insider buying. Click here to find out why I rate ASH ...